Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.71 Consensus Target Price from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has earned an average rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $85.71.

Several analysts have recently issued reports on GPCR shares. Lifesci Capital reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Cantor Fitzgerald began coverage on Structure Therapeutics in a research note on Tuesday, April 9th. They issued an “overweight” rating and a $65.00 price target on the stock.

Structure Therapeutics Trading Down 4.2 %

Shares of NASDAQ GPCR opened at $37.65 on Tuesday. The stock has a market cap of $1.75 billion and a P/E ratio of -45.36. Structure Therapeutics has a 12-month low of $21.79 and a 12-month high of $75.02. The business’s fifty day simple moving average is $41.37 and its 200-day simple moving average is $48.87.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, equities analysts forecast that Structure Therapeutics will post -0.98 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GPCR. Wellington Management Group LLP grew its holdings in shares of Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after purchasing an additional 3,504,747 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Structure Therapeutics by 835.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after purchasing an additional 1,607,525 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Structure Therapeutics by 133.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after purchasing an additional 1,333,333 shares during the last quarter. FMR LLC purchased a new position in shares of Structure Therapeutics during the first quarter worth about $29,724,000. Finally, Federated Hermes Inc. grew its holdings in shares of Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after purchasing an additional 1,157,006 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.